Renin-Angiotensin System in Diabetes

Protein Pept Lett. 2017 Nov 17;24(9):833-840. doi: 10.2174/0929866524666170728144357.

Abstract

The renin-angiotensin system (RAS) has two different axes, the classical one with the effector peptide angiotensin II and the new one with the effector peptide angiotensin (1-7). Both peptides have been shown to be involved in the pathogenesis of diabetes mellitus and its consequences, nephropathy, retinopathy and cardiomyopathy in animal models and patients. In diabetes, angiotensin II acts mostly deleterious and angiotensin (1-7) protective. In this review we summarize the knowledge about the role of the different RAS axes in diabetes mellitus and the use of drugs interfering with the RAS in the therapy of the disease.

Keywords: Renin-angiotensin system; diabetes mellitus; drugs; effector peptide angiotensin; pathogenesis; therapy..

Publication types

  • Review

MeSH terms

  • Angiotensin I / metabolism*
  • Angiotensin II / metabolism*
  • Animals
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / physiopathology
  • Humans
  • Peptide Fragments / metabolism*
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology*

Substances

  • Peptide Fragments
  • Angiotensin II
  • Angiotensin I
  • angiotensin I (1-7)